• Course
  • ELU

1 hour


Therapies on the horizon

Learning outcomes

Upon completion of this module you should:

  • Have learned about incretin based therapy
  • Understood DPP-4 inhibitors and GLP-1 agonist, their mechanism of action, glycemic and non-glycemic effects and adverse effects
  • Have a greater knowledge about the place of incretin based therapy in type 2 diabetes mellitus management.


Geeti Mahajan

Peer reviewed by:

Shagun Bindlish

Last updated

27 Apr 2016

Release date

27 Apr 2016


Accreditor credit Accreditation statement
BMJ Learning 1 credit, 1:00 hour BMJ Learning has assigned one hour of credit to this module